Hemodialysis Bloodline Systems Market Size, Share, Industry, Forecast and outlook (2024-2031)

Global Hemodialysis Bloodline Systems Market is Segmented By Product (Poly Vinyl Chloride Hemodialysis Bloodline, Polyethylene Hemodialysis Bloodline Systems, Polypropylene Hemodialysis Bloodline Systems, ABS Hemodialysis Bloodline Systems), By Therapy Type (Double-Needle Therapy, Single Needle Therapy, Haemodiafiltration), By End-User (Hospital, Clinics, Home Care Settings, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030.

Hemodialysis Bloodline Systems Market Overview

Hemodialysis Bloodline Systems Market is Expected to reach at a CAGR of 8.0% during the forecast period (2023-2030).

A hemodialysis bloodline system is a tubing system used to connect a patient's blood circulation to a dialyzer during dialysis. Renal failure patients receive hemodialysis treatment. The technique involves the patient's blood flowing through a disposable bloodstream into a dialyzer, which filters the blood, eliminates waste items, adds anti-coagulants, and returns the purified blood to the patient's body. The increasing prevalence of chronic kidney diseases, end-stage renal disease (ESRD), renal failure, and other conditions worldwide are expected to drive demand for hemodialysis bloodline systems during the forecast period. Growing research and development activities that result in the development of innovative products are likely to increase physician adoption of hemodialysis bloodline systems.

Hemodialysis Bloodline Systems Market Summary 

To Know More Insights - Download Sample

Hemodialysis Bloodline Systems Market Dynamics

The increase in prevalance of End Stage Renal Disease cases in the market will drive the market growth

As the global incidence of End Stage Renal Disease rises, the demand for dialysis treatment is expected to rise. Every year, approximately 2 million people worldwide are affected by End Stage Renal Disease (Source: United States Renal Data System Annual Data Report, 2018). The global progression of renal diseases is expected to increase the demand for dialysis to maintain proper kidney function. The prevalence of kidney-related diseases is expected to rise significantly as the world's geriatric population grows rapidly. This, in turn, is expected to drive remarkable growth in the hemodialysis and peritoneal dialysis markets during the forecast period.

Kidney diseases affect approximately 195 million women worldwide.Chronic Kidney Disease (CKD) is the sixth-leading cause of death.Globally, it is estimated that 1.7 million  people die each year due to acute kidney injury (AKI).(Source National Health Portal). Chronic kidney disease has been known as a major public health issue worldwide. The global estimated prevalence of chronic kidney disease  is 13.4 percent (11.7-15.1 percent), and the number of patients with  End Stage Kidney Disease who require renal replacement therapy ranges between 4.902 and 7.083 million. Chronic kidney disease directly impacts the global burden of morbidity and mortality due to its effect on cardiovascular risk and End Stage Kidney Disease.

Kidney failure affects nearly 750,000 patients in the United States each year, with 2 million patients worldwide.According to World Health Organization, Diabetes was the cause of 1.5 million deaths in 2019, with 48 percent of all diabetes-related deaths occurring before 70. As a result of the rising prevalence of chronic kidney disorders and kidney failure, there may be a greater demand for early diagnosis and treatment.This contributes to the growth of the global hemodialysis bloodline systems   market.

Complications during dialysis is likely to hamper the market growth   

Patients' main causes of death in dialysis are cardiac diseases (arrhythmic mechanisms or sudden cardiac arrest) and vascular access-related complications such as bleeding and infection, low blood pressure, nausea, hernia, hepatitis (B & C), and anemia.However these cases are very rare but they have a negative impact on the hemodylasis bloodline systems market. Also,high cost of treatment is the major drawback which is likely to hamper the market . Majority of   under developed and developing countries are facing this problem

COVID-19 Impact Analysis

The coronavirus pandemic poses several challenges to clinical healthcare providers and patients worldwide. The increase in the number of COVID cases and the severity rate is likely to increase the incidence of kidney damage. The global demand for renal replacement fluids has increased significantly due to the pandemic. Compared to historical US populations, the demand for RRT among COVID-19 patients has increased fivefold (4.9 percent in 2020 vs. 0.9 percent previously) (Source: American Society of Nephrology, 2021). The gradual shift toward home hemodialysis treatment before the pandemic, as well as concerns about the spread of COVID-19 infection, has significantly increased patient interest in HD treatment.

Hemodialysis Bloodline Systems Market​​​​​​​ Segmentation Analysis

The double needle therapy segment is expected to grow at the fastest CAGR during the forecast period (2021-2028)  

Over the projection period, the double needle therapy segment is expected to grow at the fastest CAGR, owing to the increased demand for dialysis, the rising number of diabetes patients and rising frequency of chronic disease such kidney failure, End Stage Renal Disease .For example, According to World Kidney Day, a global awareness campaign, chronic kidney disease affects 10% of the world's population. According to the Global Burden Study, Chronic kidney disease ranked 18th in the world regarding the total number of fatalities in 2019. Chronic kidney disease can progress to  End Stage Renal Disease  if left untreated. The National Kidney Foundation estimates that over 450,000 End Stage Renal Disease  patients are on dialysis in the United States alone each year. As a result, dialysis is the most widely used treatment for kidney disease. The rising global prevalence of chronic kidney disease is a primary driving force behind the double-needle therapy segment.

Furthermore, According to the Centers for Disease Control and  Prevention, roughly 26.7 million people, or 11.5 percent of all adults in the United States, were diagnosed with heart disease in 2019. Due to an increase in severe renal disease and comorbidities occurrences, this major patient group is anticipated to grow. Other factors, such as alcohol and cigarette use, obesity, and genetic and inherited factors, also contribute to the rise in the number of people with chronic kidney disease, which will increase the demand of double-needle therapy due to low complications post therapy.

Hemodialysis Bloodline Systems Market​​​​​​​ Geographical Share

North America region holds the largest market share of global hemodialysis bloodline systems market

North America is expected to dominate the market in the forecast period. The established market players in the region will continue to account for a substantial share in the market throughout the forecast period. According to WHO research, high-income nations spend more than 2-3 percent of their annual healthcare budget on treating end-stage kidney disease, even though people receiving treatment account for less than 0.03 percent of the overall population. Furthermore, sophisticated healthcare infrastructure and the growing prevalence of infections will positively impact the hemodialysis bloodline systems growth in the forecast period.

However, Asia-Pacific is assessed to grow the fastest during the forecast period, owing to increased healthcare spending and increased awareness about various treatment options. The cost of public and private health care in these countries is predicted to rise. As a result, producers are more inclined to concentrate their efforts on these markets. According to the World Bank Group, China's healthcare spending was 5.5 percent of GDP in 2014, and the country's healthcare spending is predicted to double by 2023. The hemodialysis bloodstream systems market is driven by strong growth in healthcare spending and rising worldwide per capita income. Shortly, improvements in health care infrastructure and government reimbursement schemes in both developed and developing nations are expected to boost the hemodialysis bloodline systems market. Other factors that contribute to the market's growth include a large patient base of various chronic diseases such as kidney failure and End Stage Renal Disease, which necessitate the use of hemodialysis bloodline system, which contribute to the growth of the Asia-Pacific hemodialysis bloodline systems market.

Hemodialysis Bloodline Systems Market​​​​​​​ Companies and Competitive Landscape

The hemodialysis bloodline systems market is highly competitive with presence of local as well as global companies. Major players operating in the global hemodialysis bloodline systems market include Baxter, Fresenius, B.Braun ,Nipro , Nikkiso, Asahi KASEI Medical, Allmed. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the biopsy devices market globally. For instance in April 2018, Fresenius Medical Care AG & Co. KGaA, the main provider of bloodstream systems, won the Red Dot Award for product design for its 6008 CAREset, which demonstrated good therapeutic benefits.

Key Developments

In Feb 2019, The Medisystems Streamline Bloodlines business was acquired by B.Braun Medical Inc. The Streamline Bloodline for the Dialog + hemodialysis system, Streamline Bloodline for the Fresenius Medical Care hemodialysis system, and Streamline Bloodline Long for the Fresenius Medical Care hemodialysis system will be among the bloodline systems acquired.

In Feb 2019, Fresenius Medical Care AG & Co.KGaA completed the $ 2 billion acquisition of Nx Stage Medical, a US-based medical device manufacturer involved in developing, producing, and marketing medical devices for in-home dialysis and critical care.

Baxter

Overview: Baxter International Inc. is an American international health care corporation headquartered in Deerfield, Illinois. The company's main focus is on kidney illness and other chronic and urgent medical diseases. Baxter's BioScience division makes recombinant and blood plasma proteins for hemophilia and other bleeding diseases, as well as plasma-based therapies for immunological deficiencies and other chronic and acute blood-related ailments, regenerative medicine products, and vaccines. Baxter's Medical Products division makes intravenous goods and other devices for delivering fluids and pharmaceuticals to patients, as well as inhalational anesthetics, contract manufacturing services, and products for treating end-stage renal diseases, such as peritoneal dialysis and hemodialysis.

Product Portfolio:

THERANOVA:  THERANOVA was created to filter a broader range of molecules from the blood than traditional hemodialysis filters, to remove large intermediate molecules (25 kDa to 45 kDa) linked to inflammation and cardiovascular health in patients with end-stage renal disease (ESRD). Its MEDIUM CUT-OFF (MCO) membrane widens the range of solutes eliminated during normal dialysis while keeping a small number of important proteins. Filtration is more similar to the natural kidney because of this particular cut-off and retention onset profile.